Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
复制标题
DOI：
10.1016/j.rmcr.2021.101560
复制
发表时间：
2021
影响因子：
1.1
通讯作者：
Panse J
中科院分区：
文献类型：
--
作者：
Daher A;Müller T;Spiesshoefer J;Dreher M;Panse J
1例71岁女性患者因抗CD 20单克隆抗体治疗导致B细胞耗竭，因COVID-19恶化入院。总体而言，患者持续出现病毒脱落、呼吸衰竭恶化和进行性肺炎，尽管接受了地塞米松和抗生素治疗，但仍未改善。在给予bamlanivimab（一种对SARS-CoV-2刺突蛋白的受体结合域具有高亲和力的单克隆抗体）后，炎症标志物迅速减少，SARS-CoV 2 RT-PCR变为阴性，患者的临床和放射学情况有所改善。总之，我们证明了使用病毒中和单克隆抗体成功治疗了严重B细胞再生障碍性贫血患者的长期COVID-19。
A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
登录
查看更多内容
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
7.5
作者：
Hill JB;Garcia D;Crowther M;Savage B;Peress S;Chang K;Deitelzweig S
通讯作者：
Deitelzweig S
影响因子：
2.4
作者：
Mishra, Kamla Prasad;Singh, Ajay Kumar;Singh, Shashi Bala
通讯作者：
Singh, Shashi Bala
影响因子：
9.4
作者：
Sepulveda, Jorge;Westblade, Lars F.;Green, Daniel A.
通讯作者：
Green, Daniel A.
影响因子：
11.8
作者：
Cao, Jianlei;Tu, Wen-Jun;Liu, Qiang
通讯作者：
Liu, Qiang